Bank Julius Baer & Co. Ltd Zurich Has $6.23 Million Stake in West Pharmaceutical Services, Inc. $WST

Bank Julius Baer & Co. Ltd Zurich lowered its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 18.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,884 shares of the medical instruments supplier’s stock after selling 6,290 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in West Pharmaceutical Services were worth $6,233,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. SYM FINANCIAL Corp boosted its stake in West Pharmaceutical Services by 5.1% during the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock valued at $225,000 after purchasing an additional 50 shares during the last quarter. Parkside Financial Bank & Trust boosted its holdings in West Pharmaceutical Services by 4.0% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,318 shares of the medical instruments supplier’s stock worth $288,000 after acquiring an additional 51 shares during the last quarter. MJP Associates Inc. ADV grew its stake in shares of West Pharmaceutical Services by 2.7% in the 2nd quarter. MJP Associates Inc. ADV now owns 1,970 shares of the medical instruments supplier’s stock worth $431,000 after acquiring an additional 52 shares in the last quarter. Horizon Investments LLC boosted its holdings in West Pharmaceutical Services by 5.8% during the first quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 57 shares during the last quarter. Finally, Pallas Capital Advisors LLC increased its stake in West Pharmaceutical Services by 1.0% in the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock valued at $1,386,000 after buying an additional 62 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. TD Cowen initiated coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They issued a “buy” rating and a $350.00 target price on the stock. Evercore ISI boosted their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. KeyCorp raised their target price on West Pharmaceutical Services from $325.00 to $350.00 and gave the company an “overweight” rating in a research report on Friday, October 24th. Cowen started coverage on West Pharmaceutical Services in a research note on Wednesday, October 29th. They set a “buy” rating on the stock. Finally, Wall Street Zen upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $349.20.

West Pharmaceutical Services Stock Up 5.1%

Shares of NYSE WST opened at $270.99 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market capitalization of $19.50 billion, a PE ratio of 40.15, a P/E/G ratio of 4.09 and a beta of 1.08. West Pharmaceutical Services, Inc. has a one year low of $187.43 and a one year high of $348.90. The business’s fifty day moving average price is $269.34 and its 200-day moving average price is $243.31.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.29. The company had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.